29.01.2015 Views

1FW2e8F

1FW2e8F

1FW2e8F

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

SECTION 1 2 3<br />

TIME TO ACT<br />

• Ensure that women’s health needs are prioritized, sexual and reproductive<br />

rights are upheld, and that bilateral aid is not permitted to constrain<br />

women’s access to reproductive health services.<br />

Corporations should agree to:<br />

• Stop lobbying for the privatization of vital public services, including<br />

healthcare and education;<br />

• Work with government efforts to regulate private healthcare providers<br />

to ensure their positive contribution to Universal Health Coverage.<br />

7) CHANGE THE GLOBAL SYSTEM FOR RESEARCH<br />

AND DEVELOPMENT (R&D) AND FOR PRICING OF<br />

MEDICINES, TO ENSURE ACCESS FOR ALL TO<br />

APPROPRIATE AND AFFORDABLE MEDICINES<br />

Relying on intellectual property as the only stimulus for R&D keeps the<br />

monopoly on making and pricing medicines in the hands of big pharmaceutical<br />

companies. This endangers lives and leads to a wider gap between rich<br />

and poor.<br />

Governments and international institutions should agree to:<br />

• Agree a global R&D treaty which makes public health – not commercial<br />

interest – the decisive factor in financing R&D;<br />

• Allocate a percentage of their national income to scientific research,<br />

including R&D for medicines;<br />

• Exclude strict intellectual property rules from trade agreements and refrain<br />

from all measures that limit government’s policy space to implement<br />

public health measures and increase their access to medicine, medical<br />

technologies, knowledge, health and education services;<br />

• Break monopolies and encourage affordable pricing of medicines via<br />

generic competition;<br />

• Scale-up investment in national medicine policy development and drug<br />

supply chains.<br />

Pharmaceutical companies should agree to:<br />

• Be transparent about the cost of R&D, and look for new ways to finance R&D<br />

beyond intellectual property;<br />

• Stop national and international lobbying for private corporate gains at the<br />

expense of public health.<br />

119

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!